Nektar Therapeutics
NASDAQ:NKTRBiotechnology
Healthcare
$32.54 -2.04%
-$1.24 today
- Market cap
- $933.51M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
52W Low $8.27High $109.00
Volume 0.86M
Average 1.00M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$208.51M
FY 2025 · Annual
Investing Cash Flow
-$1.20M
FY 2025 · Annual
Financing Cash Flow
$180.57M
FY 2025 · Annual
+328.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Depreciation & Amortization | 14.15M | 13.03M | 7.82M | 4.39M | (4.49M) |
| Deferred Income Tax | 8.02M | 2.71M | (140K) | 0 | 0 |
| Stock-Based Compensation | 94.67M | 57.32M | 33.39M | 21.61M | 12.65M |
| Change in Working Capital | (23.08M) | 492K | (19.8M) | (6.24M) | (37.02M) |
| Accounts Receivables | 12.4M | 16.51M | 4.78M | (3.05M) | 0 |
| Inventory | (509K) | (3.4M) | 699K | 497K | 0 |
| Accounts Payables | (11.69M) | 3.1M | (2.88M) | 2.67M | (625K) |
| Other Working Capital | (23.27M) | (15.72M) | (22.39M) | (6.36M) | (36.39M) |
| Other Non-Cash Items | 17.41M | (9.36M) | 62.19M | (76.51M) | (15.58M) |
| Operating Cash Flow | (412.66M) | (304.01M) | (192.61M) | (175.71M) | (208.51M) |
| Capital Expenditures | (14.99M) | (5.68M) | (865K) | (1.47M) | (171K) |
| Acquisitions (Net) | (217.77M) | 13.2M | 0 | 65.39M | (697K) |
| Purchases of Investments | (960.69M) | (467.91M) | (511.7M) | (261.71M) | (285.01M) |
| Sales of Investments | 1.18B | 826.23M | 650.88M | 340.36M | 284.68M |
| Other Investing Activities | 217.77M | 0 | 1.25M | 0 | 0 |
| Investing Cash Flow | 202.78M | 365.84M | 139.56M | 142.57M | (1.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.24M | 758K | 30K | 30.12M | 180.57M |
| Common Stock Repurchased | 0 | 0 | 0 | (3M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3M | 750K | 0 | 15M | 0 |
| Financing Cash Flow | 36.24M | 1.51M | 30K | 42.12M | 180.57M |
| Effect of Forex Changes | (92K) | (327K) | 62K | (4K) | 6K |
| Net Change in Cash | (173.74M) | 63.01M | (52.95M) | 8.98M | (29.14M) |
| Free Cash Flow | (427.65M) | (309.68M) | (193.47M) | (177.18M) | (208.68M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$164.1M
+ D&A-$4.5M
+ Stock-Based Comp$12.6M
+ Deferred Tax$0
- Working Capital-$37.0M
- Other Non-Cash-$15.6M
= Operating Cash Flow-$208.5M
- Capex-$171.0K
= Free Cash Flow-$208.7M
Analysis
FY2025 free cash flow is -$208.7M. FCF conversion is 127.2% of net income. Operating cash flow was -$208.5M, with capex of -$171.0K. The largest bridge item is Working Capital at -$37.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| S-8 | S-8 filing | Oct 20, 2026 |
Does NKTR generate free cash flow?
Nektar Therapeutics (NKTR) generated -$208.68M of free cash flow in fiscal 2025.
How much operating cash flow does NKTR produce?
Operating cash flow was -$208.51M, before capital expenditures of $171,000.00.
Continue the stock analysis
Jump to another research area for this company.